Gene therapy for pediatric cancer: State of the art and future perspectives

Journal of Biomedicine and Biotechnology

Volumn 2003, Issue 1, 2003, Pages 13-24

  Biagi, Ettore ^a   Bollard, Catherine ^a   Rousseau, Raphael ^a   Brenner, Malcolm ^a  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; CD40 LIGAND; CYTOSINE DEAMINASE; CYTOTOXIC AGENT; DAUNORUBICIN; DIHYDROFOLATE REDUCTASE; ENDOSTATIN; ENZYME; ETOPOSIDE; FIBRONECTIN; FLUCYTOSINE; FLUOROURACIL; GANCICLOVIR; GENE PRODUCT; HEMOPOIETIC GROWTH FACTOR; IMMUNOSTIMULATING AGENT; INTERLEUKIN 2; LYMPHOTACTIN; METHOTREXATE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; NITROREDUCTASE; PRODRUG METABOLIZING ENZYME; THIOTEPA; THYMIDINE KINASE; TRIMETREXATE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS VECTOR;

ADOPTIVE IMMUNOTHERAPY; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL SPECIFICITY; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DNA MODIFICATION; DRUG MECHANISM; DRUG SPECIFICITY; EFFECTOR CELL; EPSTEIN BARR VIRUS; GENE DELIVERY SYSTEM; GENE TECHNOLOGY; GENE THERAPY; GENE TRANSFER; GROWTH INHIBITION; HERPES SIMPLEX VIRUS; HODGKIN DISEASE; HUMAN; IMMUNOMODULATION; LYMPHOPROLIFERATIVE DISEASE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRECANCER; REVIEW; SENSITIVITY ANALYSIS; SUICIDE GENE THERAPY; TUMOR BLOOD FLOW; TUMOR GROWTH;

HERPES; HUMAN HERPESVIRUS 4; SIMPLEXVIRUS;

EID: 0037671807     PISSN: 11107243     EISSN: None     Source Type: Journal    
DOI: 10.1155/S1110724303209025     Document Type: Review

References (104)

1. Bleyer WA. Cancer in older adolescents and young adults: epidemiology, diagnosis, treatment, survival, and importance of clinical trials. Med Pediatr Oncol. 2002;38(1):1-10.
2. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med. 2001;7(1):33-40.
3. Rousseau RF, Bollard CM, Heslop HE. Gene therapy for paediatric leukaemia. Expert Opin Biol Ther. 2001;1(4):663-674.
4. Wivel NA, Wilson JM. Methods of gene delivery. Hematol Oncol Clin North Am. 1998;12(3):483-501.
5. Hitt MM, Graham FL. Adenovirus vectors for human gene therapy. Adv Virus Res. 2000;55:479-505.
6. High KA. Gene therapy: a 2001 perspective. Haemophilia. 2001;7(suppl 1):23-27.
7. Buchschacher GL Jr, Wong-Staal F. Development of lentiviral vectors for gene therapy for human diseases. Blood. 2000;95(8):2499-2504.
8. Xu K, Ma H, McCown TJ, Verma IM, Kafri T. Generation of a stable cell line producing high-titer self-inactivating lentiviral vectors. Mol Ther. 2001;3(1):97-104.
9. Horowitz J. Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications. Curr Opin Mol Ther. 1999;1(4):500-509.
10. Merritt JA, Roth JA, Logothetis CJ. Clinical evaluation of adenoviral-mediated p53 gene transfer: review of INGN 201 studies. Semin Oncol. 2001;28(suppl 16):105-114.
11. Balint EE, Vousden KH. Activation and activities of the p53 tumour suppressor protein. Br J Cancer. 2001;85(12):1813-1823.
12. Watanabe T, Sullenger BA. Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts. Proc Natl Acad Sci USA. 2000;97(15):8490-8494.
13. Komata T, Kondo Y, Koga S, Ko SC, Chung LW, Kondo S. Combination therapy of malignant glioma cells with 2-5A-antisense telomerase RNA and recombinant adenovirus p53. Gene Ther. 2000;7(24):2071-2079.
14. Beltinger C, Uckert W, Debatin KM. Suicide gene therapy for pediatric tumors. J Mol Med. 2001;78(11):598-612.
15. Beltinger C, Fulda S, Kammertoens T, Meyer E, Uckert W, Debatin KM. Herpes simplex virus thymidine kinase/ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases. Proc Natl Acad Sci USA. 1999;96(15):8699-8704.
16. Nanda D, Vogels R, Havenga M, Avezaat CJ, Bout A, Smitt PS. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase. Cancer Res. 2001;61(24):8743-8750.
17. Bansal K, Engelhard HH. Gene therapy for brain tumors. Curr Oncol Rep. 2000;2(5):463-472.
18. Engelhard HH. Gene therapy for brain tumors: the fundamentals. Surg Neurol. 2000;54(1):3-9.
19. Packer RJ, Raffel C, Villablanca JG, et al. Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration. J Neurosurg. 2000;92(2):249-254.
20. Hurwitz MY, Marcus KT, Chevez-Barrios P, Louie K, Aguilar-Cordova E, Hurwitz RL. Suicide gene therapy for treatment of retinoblastoma in a murine model. Hum Gene Ther. 1999;10(3):441-448.
21. Hurwitz RL, Brenner MK, Poplack DG, Horowitz MC. Retinoblastoma treatment. Science. 1999;285(5428):663-664.
22. Mullen CA, Kilstrup M, Blaese RM. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci USA. 1992;89(1):33-37.
23. Castleden SA, Chong H, Garcia-Ribas I, et al. A family of bicistronic vectors to enhance both local and systemic antitumor effects of HSVtk or cytokine expression in a murine melanoma model. Hum Gene Ther. 1997;8(17):2087-2102.
24. Palu G, Cavaggioni A, Calvi P, et al. Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans. Gene Ther. 1999;6(3):330-337.
25. Freund CT, Sutton MA, Dang T, Contant CF, Rowley D, Lerner SP. Adenovirus-mediated combination suicide and cytokine gene therapy for bladder cancer. Anticancer Res. 2000;20(3A):1359-1365.
26. Toda M, Martuza RL, Rabkin SD. Combination suicide/cytokine gene therapy as adjuvants to adefective herpes simplex virus-based cancer vaccine. Gene Ther. 2001;8(4):332-339.
27. Majumdar AS, Zolotorev A, Samuel S, et al. Efficacy of herpes simplex virus thymidine kinase in combination with cytokine gene therapy in an experimental metastatic breast cancer model. Cancer Gene Ther. 2000;7(7):1086-1099.
28. Jones RK, Pope IM, Kinsella AR, Watson AJ, Christmas SE. Combined suicide and granulocyte-macrophage colony-stimulating factor gene therapy induces complete tumor regression and generates antitumor immunity. Cancer Gene Ther. 2000;7(12):1519-1528.
29. Avvakumov N, Mymryk JS. New tools for the construction of replication-competent adenoviral vectors with altered E1A regulation. J Virol Methods. 2002;103(1):41-49.
30. Bonini C, Ferrari G, Verzeletti S, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 1997;276(5319):1719-1724.
31. Verzeletti S, Bonini C, Marktel S, et al. Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: clinical follow-up and improved new vectors. Hum Gene Ther. 1998;9(15):2243-2251.
32. Thomis DC, Marktel S, Bonini C, et al. A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood. 2001;97(5):1249-1257.
33. Kleinman HK, Liau G. Gene therapy for antiangio-genesis. J Natl Cancer Inst. 2001;93(13):965-967.
34. Sauter BV, Martinet O, Zhang WJ, Mandeli J, Woo SL. Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc Natl Acad Sci USA. 2000;97(9):4802-4807.
35. Jin X, Bookstein R, Wills K, et al. Evaluation of endostatin antiangiogenesis gene therapy in vitro and in vivo. Cancer Gene Ther. 2001;8(12):982-989.
36. Feldman AL, Alexander HR, Hewitt SM, et al. Effect of retroviral endostatin gene transfer on subcutaneous and intraperitoneal growth of murine tumors. J Natl Cancer Inst. 2001;93(13):1014-1020.
37. Ma HI, Lin SZ, Chiang YH, et al. Intratumoral gene therapy of malignant brain tumor in a rat model with angiostatin delivered by adeno-associated viral (AAV) vector. Gene Ther. 2002;9(1):2-11.
38. Ma HI, Guo P, Li J, et al. Suppression of intracranial human glioma growth after intramuscular administration of an adeno-associated viral vector expressing angiostatin. Cancer Res. 2002;62(3):756-763.
39. Moscow JA, Huang H, Carter C, et al. Engraftment of MDR1 and NeoR gene-transduced hematopoietic cells after breast cancer chemotherapy. Blood. 1999;94(1):52-61.
40. Plumb JA, Bilsland A, Kakani R, et al. Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954. Oncogene. 2001;20(53):7797-7803.
41. Allay JA, Galipeau J, Blakley RL, Sorrentino BP. Retroviral vectors containing a variant dihydrofolate reductase gene for drug protection and in vivo selection of hematopoietic cells. Stem Cells. 1998;16(suppl 1):223-233.
42. Brenner MK, Rill DR, Holladay MS, et al. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet. 1993;342(8880):1134-1137.
43. Brenner M, Mirro J Jr, Hurwitz C, et al. Autologous bone marrow transplant for children with AML in first complete remission: use of marker genes to investigate the biology of marrow reconstitution and the mechanism of relapse. Hum Gene Ther. 1991;2(2):137-159.
44. Santana VM, Brenner MK, Ihle J, et al. A phase I trial of high-dose carboplatin and etoposide with autologous marrow support for treatment of stage D neuroblastoma in first remission: use of marker genes to investigate the biology of marrow reconstitution and the mechanism of relapse. Hum Gene Ther. 1991;2(3):257-272.
45. Cornetta K, Tricot G, Broun ER, et al. Retroviral-mediated gene transfer of bone marrow cells during autologous bone marrow transplantation for acute leukemia. Hum Gene Ther. 1992;3(3):305-318.
46. Deisseroth AB, Kantarjian H, Talpaz M, et al. Autologous bone marrow transplantation for CML in which retroviral markers are used to discriminate between relapse which arises from systemic disease remaining after preparative therapy versus relapse due to residual leukemia cells in autologous marrow: a pilot trial. Hum Gene Ther. 1991;2(4):359-376.
47. Brenner MK, Rill DR, Heslop HE, et al. Gene marking after bone marrow transplantation. Eur J Cancer. 1994;30A(8):1171-1176.
48. Rill DR, Sycamore DL, Smith SS, et al. Long term in vivo fate of human hemopoietic cells transduced by moloney-based retroviral vectors. Blood. 2000;96(11):844a.
49. Heslop HE, Ng CYC, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 1996;2(5):551-555.
50. Rooney CM, Smith CA, Ng CYC, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998;92(5):1549-1555.
51. Roskrow MA, Rooney CM, Heslop HE, et al. Administration of neomycin resistance gene marked EBV specific cytotoxic T-lymphocytes to patients with relapsed EBV-positive Hodgkin disease. Hum Gene Ther. 1998;9(8):1237-1250.
52. Bollard CM, Rooney CM, Huls MH, et al. Long term follow-up of patients who received EBV specific CTLs for the prevention or treatment of EBV lymphoma. Blood. 2000;96(11):478a.
53. Rousseau RF, Hirschmann-Jax C, Takahashi S, Brenner MK. Cancer vaccines. Hematol Oncol Clin North Am. 2001;15(4):741-773.
54. Dilloo D, Bacon K, Holden W, et al. Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat Med. 1996;2(10):1090-1095.
55. Soiffer R, Lynch T, Mihm M, et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA. 1998;95(22):13141-13146.
56. Nelson WG, Simons JW, Mikhak B, et al. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies. Cancer Chemother Pharmacol. 2000;46(suppl):S67-S72.
57. DeAngelo DJ, Dranoff G, Galinsky I, et al. A Phase I study of vaccination with lethally irradiated, autologous myeloblasts engineered by adenoviral-mediated gene transfer to secrete granulocyte-macrophage colony-stimulating factor. Blood. 2001;98:463a.
58. Asher AL, Mule JJ, Kasid A, et al. Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors. J Immunol. 1991;146(9):3227-3234.
59. Hock H, Dorsch M, Diamantstein T, Blankenstein T. Interleukin 7 induces CD4+ T cell-dependent tumor rejection. J Exp Med. 1991;174(6):1291-1298.
60. Watanabe Y, Kuribayashi K, Miyatake S, et al. Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc Natl Acad Sci USA. 1989;86(23):9456-9460.
61. Leimig T, Foreman N, Rill D, Coze C, Holladay M, Brenner M. Immunomodulatory effects of human neuroblastoma cells transduced with a retroviral vector encoding interleukin-2. Cancer Gene Ther. 1994;1(4):253-258.
62. Van Kooten C, Banchereau J. CD40-CD40 ligand: a multifunctional receptor-ligand pair. Adv Immunol. 1996;61:1-77.
63. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392(6673):245-252.
64. Dilloo D, Brown M, Roskrow M, et al. CD40 ligand induces an antileukemia immune response in vivo. Blood. 1997;90(5):1927-1933.
65. Fujita N, Kagamu H, Yoshizawa H, et al. CD40 ligand promotes priming of fully potent antitumor CD4(+) T cells in draining lymph nodes in the presence of apoptotic tumor cells. J Immunol. 2001;167(10):5678-5688.
66. Kato K, Cantwell MJ, Sharma S, Kipps TJ. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest. 1998;101(5):1133-1141.
67. Guinan EC, Gribben JG, Boussiotis VA, Freeman GJ, Nadler LM. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood. 1994;84(10):3261-3282.
68. Ranheim EA, Kipps TJ. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med. 1993;177(4):925-935.
69. Bowman L, Grossmann M, Rill D, et al. IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood. 1998;92(6):1941-1949.
70. Bowman LC, Grossmann M, Rill D, et al. Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma. Hum Gene Ther. 1998;9(9):1303-1311.
71. Brenner MK, Heslop H, Krance R, et al. Phase I study of chemokine and cytokine gene-modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma using an adenoviral vector. Hum Gene Ther. 2000;11(10):1477-1488.
72. Riddell SR, Elliott M, Lewinsohn DA, et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med. 1996;2(2):216-223.
73. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333(16):1038-1044.
74. Heslop HE, Ng CYC, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 1996;2(5):551-555.
75. Economou JS, Belldegrun AS, Glaspy J, et al. In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial. J Clin Invest. 1996;97(2):515-521.
76. Brodie SJ, Lewinsohn DA, Patterson BK, et al. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat Med. 1999;5(1):34-41.
77. Rooney CM, Smith CA, Ng CYC, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995;345(8941):9-13.
78. Regn S, Raffegerst S, Chen X, Schendel D, Kolb HJ, Roskrow M. Ex vivo generation of cytotoxic T lymphocytes specific for one or two distinct viruses for the prophylaxis of patients receiving an allogeneic bone marrow transplant. Bone Marrow Transplant. 2001;27(1):53-64.
79. O'Reilly RJ, Small TN, Papadopoulos E, Lucas K, Lacerda J, Koulova L. Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev. 1997;157:195-216.
80. Gustafsson A, Levitsky V, Zou JZ, et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood. 2000;95(3):807-814.
81. Heslop HE, Rooney CM. Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Immunol Rev. 1997;157:217-222.
82. Bollard C, Onishi H, Huls M, et al. Long-term follow-up of patients who received EBV-specific CTLs for the prevention or treatment of EBV-associated lymphoproliferative disease. Biol Blood Marrow Transplant. 2001;7(2):61.
83. Gottschalk S, Ng CYC, Perez M, et al. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood. 2001;97(4):835-843.
84. Claviez A, Tiemann M, Wagner HJ, Dreger P, Suttorp M. Epstein-Barr virus- associated posttransplant lymphoproliferative disease after bone marrow transplantation mimicking graft-versus-host disease. Pediatr Transplant. 2000;4(2):151-155.
85. Beaty O 3rd, Hudson MM, Greenwald C, et al. Subsequent malignancies in children and adolescents after treatment for Hodgkin's disease. J Clin Oncol. 1995;13(3):603-609.
86. Aisenberg AC. Problems in Hodgkin's disease management. Blood. 1999;93(3):761-779.
87. Bollard C, Gahn B, Aguilar L, et al. Cytotoxic T lymphocyte therapy for EBV+ Hodgkin disease. Blood. 2000;96(11):576a.
88. Poppema S, Potters M, Visser L, van den Berg AM. Immune escape mechanisms in Hodgkin's disease. Ann Oncol. 1998;9(suppl 5):S21-S24.
89. Gahn B, Siller-Lopez F, Pirooz AD, et al. Enhanced immune response to the Epstein-Barr virus (EBV) antigen LMP2a using recombinant adenovirus transduced dendritic cells: a potential strategy for EBV-positive Hodgkin's lymphoma. Blood. 2000;96(11), suppl 1:829a.
90. Su Z, Peluso MV, Raffegerst SH, Schendel DJ, Roskrow MA. The generation of LMP2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgkin disease. Eur J Immunol. 2001;31(3):947-958.
91. Dukers DF, Jaspars LH, Vos W, et al. Quantitative immunohistochemical analysis of cytokine profiles in Epstein-Barr virus-positive and -negative cases of Hodgkin's disease. J Pathol. 2000;190(2):143-149.
92. Poppema S, Potters M, Visser L, van den Berg AM. Immune escape mechanisms in Hodgkin's disease. Ann Oncol. 1998;9(suppl 5):S21-S24.
93. Scarpa S, Coppa A, Ragano-Caracciolo M, et al. Transforming growth factor beta regulates differentiation and proliferation of human neuroblastoma. Exp Cell Res. 1996;229(1):147-154.
94. Bollard CM, Rossig C, Calonge MJ, et al. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood. 2002;99(9):3179-3187.
95. Werner-Wasik M, Winkler P, Uri A, Goldwein J. Nasopharyngeal carcinoma in children. Med Pediatr Oncol. 1996;26(5):352-358.
96. Pao WJ, Hustu HO, Douglass EC, Beckford NS, Kun LE. Pediatric nasopharyngeal carcinoma: long term follow-up of 29 patients. Int J Radiat Oncol Biol Phys. 1989;17(2):299-305.
97. Wang CC, Chen ML, Hsu KH, et al. Second malignant tumors in patients with nasopharyngeal carcinoma and their association with Epstein-Barr virus. Int J Cancer. 2000;87(2):228-231.
98. Chua D, Huang J, Zheng B, et al. Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma. Int J Cancer. 2001;94(1):73-80.
99. McGuinness RP, Ge Y, Patel SD, et al. Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor. Hum Gene Ther. 1999;10(2):165-173.
100. Ren-Heidenreich L, Hayman GT, Trevor KT. Specific targeting of EGP-2+ tumor cells by primary lymphocytes modified with chimeric T cell receptors. Hum Gene Ther. 2000;11(1):9-19.
101. Gonzalez S, Naranjo A, Peng J, Chang W, Wright C, Jensen M. Genetic engineering of T cells for redirected neuroblastoma recognition: preclinical studies supporting the initiation of a FDA-authorized clinical trial. Molecular Therapy. 2001;3(5):S369-S370.
102. Mitsuyasu RT, Anton PA, Deeks SG, et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood. 2000;96(3):785-793.
103. Walker RE, Bechtel CM, Natarajan V, et al. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood. 2000;96(2):467-474.
104. Rossig C, Bollard CM, Nuchtern JG, Rooney CM, Brenner MK. Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood. 2002;99(6):2009-2016.